Parkinsons Disease Epidemiology Forecast

DelveInsight's 'Parkinson's Disease - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Parkinson's Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Parkinson's Disease Understanding

The DelveInsight Parkinson's Disease epidemiology report gives a thorough understanding of the Parkinson's Disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Parkinson's Disease in the US, Europe, and Japan. The report covers the detailed information of the Parkinson's Disease epidemiology scenario in seven major countries (US, EU5, and Japan).


Parkinson's Disease Epidemiology Perspective by DelveInsight

The Parkinson's Disease epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Parkinson's Disease epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Parkinson's Disease epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Parkinson's Disease Detailed Epidemiology Segmentation

The Parkinson's Disease epidemiology covered in the report provides historical as well as forecasted Parkinson's Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Parkinson's Disease report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Parkinson's Disease report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Parkinson's Disease Epidemiology Report and Model provide an overview of the risk factors and global trends of Parkinson's Disease in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Parkinson's Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Parkinson's Disease
  • The report provides the segmentation of the Parkinson's Disease epidemiology


Report Highlights

  • 11-Year Forecast of Parkinson's Disease epidemiology
  • 7MM Coverage
  • Total Cases of Parkinson's Disease
  • Total Cases of Parkinson's Disease according to segmentation
  • Diagnosed cases of Parkinson's Disease


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Parkinson's Disease?
  • What are the key findings pertaining to the Parkinson's Disease epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Parkinson's Disease across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Parkinson's Disease?
  • What are the currently available treatments of Parkinson's Disease?


Reasons to buy

  • The Parkinson's Disease Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Parkinson's Disease market
  • Quantify patient populations in the global Parkinson's Disease market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Parkinson's Disease therapeutics in each of the markets covered
  • Understand the magnitude of Parkinson's Disease population by its epidemiology
  • The Parkinson's Disease Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Parkinson's Disease

3. Parkinson's Disease: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Parkinson's Disease Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Parkinson's Disease Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Parkinson's Disease Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Parkinson's Disease Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Parkinson's Disease Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Parkinson's Disease Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Parkinson's Disease Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Parkinson's Disease Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Parkinson's Disease Treatment and Management

6.2. Parkinson's Disease Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Parkinson's Disease Epidemiology in 7MM (2017-2030)

Table 2 Parkinson's Disease Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Parkinson's Disease Epidemiology in the United States (2017-2030)

Table 4 Parkinson's Disease Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Parkinson's Disease Epidemiology in Germany (2017-2030)

Table 6 Parkinson's Disease Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Parkinson's Disease Epidemiology in France (2017-2030)

Table 8 Parkinson's Disease Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Parkinson's Disease Epidemiology in Italy (2017-2030)

Table 10 Parkinson's Disease Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Parkinson's Disease Epidemiology in Spain (2017-2030)

Table 12 Parkinson's Disease Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Parkinson's Disease Epidemiology in the United Kingdom (2017-2030)

Table 14 Parkinson's Disease Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Parkinson's Disease Epidemiology in Japan (2017-2030)

Table 16 Parkinson's Disease Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Parkinson's Disease Epidemiology in 7MM (2017-2030)

Figure 2 Parkinson's Disease Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Parkinson's Disease Epidemiology in the United States (2017-2030)

Figure 4 Parkinson's Disease Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Parkinson's Disease Epidemiology in Germany (2017-2030)

Figure 6 Parkinson's Disease Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Parkinson's Disease Epidemiology in France (2017-2030)

Figure 8 Parkinson's Disease Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Parkinson's Disease Epidemiology in Italy (2017-2030)

Figure 10 Parkinson's Disease Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Parkinson's Disease Epidemiology in Spain (2017-2030)

Figure 12 Parkinson's Disease Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Parkinson's Disease Epidemiology in the United Kingdom (2017-2030)

Figure 14 Parkinson's Disease Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Parkinson's Disease Epidemiology in Japan (2017-2030)

Figure 16 Parkinson's Disease Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Parkinson's Disease Epidemiology
  • Parkinson's Disease
  • Parkinson's Disease Pipeline
  • Parkinson's Disease Companies
  • Parkinson's Disease prevalent popu...
  • Parkinson's Disease incident popul...
  • Parkinson's Disease patients diagn...
  • Parkinson's Disease treatment algo...

Forward to Friend

Need A Quote